Autologus dendritic cell vaccine for chronic hepatitis B carriers: A pilot, open label, clinical trial in human volunteers

Vaccine

Volumn 28, Issue 13, 2010, Pages 2497-2504

  Luo, Jin ^a,b   Li, Jun ^c   Chen, Rui L ^d   Nie, Lei ^e   Huang, Jie ^f   Liu, Zheng W ^g   Luo, Lin ^h   Yan, Xiao J ^a,i  

^a State Key Laboratory of Cancer Biology   (China)

^b Taizhou Hepatopathy Centre   (China)

^c THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^d SHAANXI PROVINCIAL PEOPLE S HOSPITAL   (China)

^e XI'AN MEDICAL UNIVERSITY   (China)

^f XI'AN JIAOTONG UNIVERSITY   (China)

^g First Affiliated Hospital   (China)

^h Maternal and Child Care Service Centre of Hanzhong City   (China)

ⁱ Biologic Diagnosis and Therapy Engineering Research Center   (China)

Author keywords

Chronic hepatitis B; Dendritic cell vaccine; Immunotherapy

Indexed keywords

ALANINE AMINOTRANSFERASE; B7 ANTIGEN; CD14 ANTIGEN; CD86 ANTIGEN; DENDRITIC CELL VACCINE; HEPATITIS B VACCINE; HEPATITIS B(E) ANTIGEN; HLA ANTIGEN CLASS 1; HLA DR ANTIGEN; VIRUS DNA;

ADULT; ARTICLE; CELL STRUCTURE; CHRONIC HEPATITIS; CLINICAL TRIAL; CONTROLLED STUDY; DENDRITIC CELL; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG RESPONSE; DRUG SAFETY; DYSPNEA; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; PILOT STUDY; POINT MUTATION; PRIORITY JOURNAL; SEROCONVERSION; VACCINATION; VIRUS IMMUNITY;

ADOLESCENT; ADULT; ALANINE TRANSAMINASE; ANTIGENS, VIRAL; DENDRITIC CELLS; DNA, VIRAL; FEMALE; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMAN EXPERIMENTATION; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME; VACCINES; YOUNG ADULT;

EID: 77649191875     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.01.038     Document Type: Article

References (44)

1. Lai C.L., Ratziu V., Yuen M.F., and Poynard T. Viral hepatitis B. Lancet 362 (2003) 2089-2094
2. + cells in liver damage and viral control during persistent hepatitis B virus infection. J Exp Med 191 (2000) 1269-1280
3. Reignat S., Webster G.J., Brown D., Ogg G.S., King A., Seneviratne S.L., et al. Escaping high viral load exhaustion: CD8 bcells with altered tetramer binding in chronic hepatitis B virus infection. J Exp Med 195 (2002) 1089-1110
4. Shimizu Y., Guidotti L.G., Fowler P., and Chisari F.V. Dentritic cell immunization breaks cytotoxic T lymphocyte tolerance in hepatitis B virus transgenic mice. J Immunol 161 (1998) 4520-4529
5. Tavakoli S., et al. Phenotype and function of monocyte derived dendritic cells in chronic hepatitis B virus infection. J Gen Virol 85 (2004) 2829-2836
6. Hoofnagle J.H., and Dibisceglie A.M. The treatment o f chronic viral hepatitis. N Engl J Med 5336 (1997) 347-356
7. Fung S.K., and Lok A.S. Update on viral hepatitis in 2004. Curr Opin Gastroentrol 21 (2005) 300-307
8. Steinmanb R.M. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 9 (1991) 271-296
9. Akbar S.M. Dendritic cells and chronic hepatitis virus carriers. Intervirology 44 (2001) 199-208
10. Kurose K. Production of antibody to hepatitis B surface antigen (anti-HBs) by murine hepatitis B virus carriers: neonatal tolerance versus antigen presentation by dendritic cells. Immunology 92 (1997) 494-500
11. Wang F.S., et al. Dysfunction of peripheral blood dendritic cells from patients with chronic hepatitis B virus infection. World J Gastroenterol 7 (2001) 537-544
12. Babatz J., Rollig C., et al. Induction of cellular immune response against carcinoembryonic antigen in patients with metastatic tumors after vaccination with altered peptide ligand-loaded dendritic cells. Cancer Immunol Immunother (2005) 10.1007/s00262-005-0021-x
13. Inaba K., Metlay J.P., Crowley M.T., and Steinman R.M. Dendritic cells pulsed with protein antigen in vivo can prime antigen-specific. MHC-restricted T cells in situ. J Exp Med 172 4 (1990) 631-640
14. Sornasse T., Flamand V., De Becker G., Bazin F., et al. Antigen-pulsed dendritic cells can efficiently induce an antibody response in vivo. J Exp Med 175 1 (1992) 15-21
15. Hu X., Chakraborty N.G., Sporn J.R., Kurtzman S.H., Ergin M.T., and Mukerji B. Enhancement of cytolytic T lymphocyte precursor frequency in melanoma patients following immunization with MAGE-1 peptide loaded antigen presenting cell-based vaccine. Cancer Res 56 11 (1996) 2479-2483
16. Caux C., Liu Y.-J., and Banchereau J. Recent advances in the study of dendritic cells. Immunol Today 16 1 (1995) 2-4
17. Lu W., Wu X., Lu Y., Guo W., and Andrieu J.-M. Therapeutic dendritic-cell vaccine for semian AIDS. Nat Med 9 (2003) 27-32
18. Chisari F.V., Pinkert C.A., Milich D.R., Filippi P., McLachlan A., Palmiter R.D., et al. Transgenic mouse model of the chronic hepatitis B surface antigen carrier state. Science 230 (1985) 1157-1160
19. Akbar S.M., Onji M., Inaba K., Yamamura K., and Ohta Y. Low responsiveness of hepatitis B virus-transgenic mice in antibody response to T-cell-dependent antigen: defect in antigenic-presenting activity of dendritic cells. Immunology 78 (1993) 468-475
20. Akbar S.M., et al. Production and efficacy of a dendritic cell-based therapeutic vaccine for murine chronic hepatitis B virus carriers. Int J Mol Med 14 (2004) 295-299
21. Fazle Akbar S.M., Furukawa S., Onji M., Murata Y., Niya T., Kanno S., et al. Safety and efficacy of hepatitis B surface antigen-pulsed dendritic cells in human volunteers. Hepatol Res 29 (2004) 136-141
22. Chen M., Li Y.G., Zhang D.Z., Wang Z.Y., et al. Therapeutic effect of autologous dendritic cell vaccine on patients with chronic hepatitis B: a clinical study. World J Gastroenterol 11 (2005) 1806-1808
23. Zhang Y., Li S., Shan M., Pan X., Zhuang K., He L., et al. Hepatitis B virus core antigen epitopes presented by HLA-A2 single-chain trimers induce functional epitope-specific CD8+ T-cell responses in HLA-A2.1/kb transgenic mice. Immunology 121 1 (2007) 105-112
24. Vitiello A., Ishioka G., Grey H.M., Rose R., Farness P., LaFond R., et al. Development of a lipopeptide-based therapeutic vaccine to treat Chronic HBV infection. J Clin Invest 95 1 (1995) 341-349
25. Lu W., Arraes L.C., Ferreira W.T., and Andrieu J.-M. Therapeutic dendritic-cell vaccine for chronic HIV-I infection. Nat Med 10 (2004) 1350-1365
26. Bai Y.J., Zhao J.R., Lv G.T., Zhang W.H., Wang Y., and Yan X.J. Rapid and high throughput detection of HBV YMDD mutants with fluorescence polarization. World J Gastroenterol 9 (2003) 2344-2347
27. Lampertico P., Del Ninno E., Manzin A., Donato M.F., Rumi M.G., Lunghi G., et al. A randomized, controlled trial of a 24-month course of interferon alpha 2b in patients with chronic hepatitis B who had hepatitis B virus DNA without hepatitis e antigen in serum. Hepatology 26 (1997) 1621-1625
28. Fattovich G., Farci P., Rugge M., Brollo L., Mandas A., Pontisso P., et al. A randomized controlled trial lymphoblastoid interferon-alpha in patients with chronic hepatitis B lacking HBeAg. Hepatology 5 4 (1992) 584-589
29. Marcellin P., Chang T.T., Lim S.G., Sievert W., Tong M., Arterburn S., et al. Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. Hepatology 48 3 (2008) 750-758
30. Fu L., and Cheng Y.C. Role of additional mutations outside the YMDD motif of hepatitis B virus polymerase in L(-) Sddc(3TC) resistance. Biochem Pharmacol 55 (1998) 1567-1572
31. Cooksley W.G., Piratvisuth T., Lee S.D., Mahachai V., Chao Y.C., Tanwandee T., et al. Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hepatol 10 (2003) 298-305
32. Lok A.S., Lai C.L., Leung N., Yao G.B., Cui Z.Y., Schiff E.R., et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 125 (2003) 1714-1722
33. Chevallier M., Guerret S., Chossegros P., Gerard F., and Grimaud J.A. A histological semiquantitative scoring system for evaluation of hepatic fibrosis in needle liver biopsy specimens: comparison with morphometric studies. Hpatology 20 (1994) 349-355
34. George K.K., Piratvisuth T., Luo K.X., et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 352 (2005) 2682-2694
35. Alexander G., Baba C.S., Chetri K., Negi T.S., and Choudhuri G. High rates of early HBeAg seroconversion and relapse in Indian patients of chronic hepatitis B treated with Lamivudine: results of an open labeled trial. BMC Gastroenterol 15 (2005) 5-29
36. Lee K.M., Cho S.W., Kim S.W., Kim H.J., Hahm K.B., and Kim J.H. Effect of virological response on post-treatment durability of lamivudine-induced HBeAg seroconversion. J Viral Hepatol 9 (2002) 208-212
37. Perrillo R.P., Lai C.L., Liaw Y.F., Dienstag J.L., Schiff E.R., Schalm S.W., et al. Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. Hepatology 36 (2002) 186-194
38. Xu X.-W., and Chen Y.-G. Current therapy with nucleoside/nucleotide analogs for patients with chronic hepatitis B. Hepatobiliary Pancreat Dis Int 5 (2006) 350-359
39. Kweon Y.O., and Kang K.H. Pretreatment ALT level and histologic 1 activity as predictors of HBeAg loss in lamivudine treatment for chronic hepatitis B. Korean J Hepatol 10 (2004) 31-41
40. Saikia N., Talukdar R., Mazumder S., Khanna S., and Tandon R. Management of patients with HBeAg-negative chronic hepatitis B. Postgrad Med J 83 (2007) 32-39
41. Hadziyannis S.J., Tassopoulos N.C., Heathcote E.J., Chang T.T., Kitis G., Rizzetto M., et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 131 (2006) 1743-1751
42. Kojiro M., Shimamatsu K., and Kage M. Pathomorphologic comparison of hepatitis C virus-related and hepatitis B virus-related cirrhosis bearing hepatocellular carcinoma. Princess Takamatsu Symp 25 (1995) 179-184
43. Reinke P., David H., Uerlings I., and Decker T. Electron microscopy of liver in patients with chronic haemodialysis. Exp Pathol 42 2 (1991) 65-75
44. Yalcin K., Degertekin H., Yildiz F., and Celik Y. Comparison of 12-month courses of interferon alpha 2b lamivudine combination therapy and interferon alpha 2b monotherapy among patients with untreated hepatitis chronic hepatitis B. Clin Infect Dis 36 (2003) 1516-1522